- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07694128
Bioequivalence Study to Compare Selexipag 400 Microgram Film Coated Tablets Versus Uptravi® (Selexipag) 400 Microgram Film Coated Tablets
3 de julio de 2026 actualizado por: Humanis Saglık Anonim Sirketi
An Open Label, Balanced, Randomized, Single Dose, Three Treatment, Three Sequence, Three Period, Three Way Crossover Oral Bioequivalence Study to Compare Selexipag 400 Microgram Film Coated Tablets Versus Uptravi® (Selexipag) 400 Microgram Film Coated Tablets in Fed Condition.
An open label, randomized, Three treatment, Three sequence, Three period, Three way crossover, single dose oral bioequivalence study to compare Selexipag 400 microgram film coated tablets versus Uptravi® (selexipag) 400 microgram film coated tablets in fed condition.
Descripción general del estudio
Estado
Terminado
Condiciones
Tipo de estudio
Intervencionista
Inscripción (Actual)
30
Fase
- Fase 1
Contactos y Ubicaciones
Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.
Ubicaciones de estudio
-
-
Gujarat
-
Ahmedabad, Gujarat, India, 380 015
- Veeda Clinical Research Ltd.
-
-
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
Acepta Voluntarios Saludables
Sí
Descripción
Inclusion Criteria:
- Participants aged between 18 to 55 years (both inclusive).
- Participants' weight within normal range according to normal values for Body Mass Index (between 18.50 to 30.00 kg/m2) (both inclusive) with minimum of 45 kg weight.
- Participants with normal health as determined by personal medical history, clinical examination and laboratory examinations within Predefined site Normal range [Annexure III].
- Participants having clinically acceptable 12-lead electrocardiogram (ECG).
- Participants having clinically acceptable chest X-Ray (PA view), if taken.
- Participants having negative urine screen for drugs of abuse (including amphetamines, barbiturates, benzodiazepines, marijuana, cocaine and morphine).
- Participants having negative urine alcohol test / breath alcohol test.
- Non-smoker.
- Participants willing to adhere to the protocol requirements and to provide written informed consent.
- For Male Participants: Participants willing to follow approved birth control methods (a double barrier method) for the duration of the study as judged by the investigator(s), such as (a double barrier method) condom with spermicide, Condom with diaphragm, or abstinence. Participants willing to refrain from donating sperm during the study period
- For Female Participants: Female of child bearing potential practicing an acceptable method of birth control for the duration of the study as judged by the investigator(s), such as intrauterine device (IUD), abstinence, bilateral tubal ligation or double barrier contraception, i.e., condom + diaphragm, condom + spermicidal or foam or Postmenopausal for at least 1 year, or if less than 1 year, then following acceptable contraceptive measures as mentioned above
- Participants having negative urine pregnancy test at screening and negative serum beta-hCG pregnancy test on admission day of period 01 (only for female Participants).
Exclusion Criteria:
- Hypersensitivity to Selexipag or ondansetron, paracetamol, or related class of drugs or any of its excipients.
- History or presence of significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, endocrine, immunological, dermatological, neurological, urogenital or psychiatric disease or disorder.
- Any treatment which could bring about induction or inhibition of hepatic microsomal enzyme system within 30 days prior to admission in period 01.
- Presence of alcoholism or drug abuse.
- History or presence of asthma, urticaria or other significant allergic reactions.
- History or presence of significant gastric and/or duodenal ulceration.
- History or presence of significant thyroid disease, adrenal dysfunction, organic intracranial lesion such as pituitary tumor.
- History or presence of serotonin syndrome (including altered mental status, autonomic instability and neuromuscular abnormalities) following the concomitant use of ondansetron and other serotonergic drugs (including SSRIs and SNRIs).
- History or presence of cancer or basal or squamous cell carcinoma.
- Difficulty with donating blood.
- Difficulty in swallowing solids dosage form like tablets or capsules.
- Use of any prescribed medication or OTC medication including vaccines, vitamins and herbal remedies during last 30 days prior to admission in period 01.
- Major illness within past 3 months.
- Participant who have donated blood (1 unit) or participation in a drug research study within past 90 days prior to the first dose of the study drug.
- Consumption of xanthine-containing foods or beverages (like chocolate, tea, coffee or cola drinks), tobacco containing products or alcohol or any alcohol containing products within 48.00 hours prior to admission in period 01.
- Consumption of grapefruit or grapefruit juice containing products within 72.00 hours prior to admission of period 01.
- Positive screening test for any one or more: HIV, Hepatitis B and Hepatitis C.
- History or presence of significant easy bruising or bleeding.
- History or presence of significant recent trauma.
- Participants who have been on an abnormal diet (for whatever reason) during the four weeks preceding the study.
- Female Participants who are currently breast feeding.
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Otro
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación cruzada
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Selexipag film coated tablets (T1)
Selexipag 400 microgram film coated tablets
|
1 tablet of Selexipag 400 microgram film coated tablets
1 tablet of Selexipag 400 microgram film coated tablets
1 tablet of Uptravi® (selexipag) 400 microgram film coated tablets
|
|
Experimental: Selexipag film coated tablets (T2)
Selexipag 400 microgram film coated tablets
|
1 tablet of Selexipag 400 microgram film coated tablets
1 tablet of Selexipag 400 microgram film coated tablets
1 tablet of Uptravi® (selexipag) 400 microgram film coated tablets
|
|
Comparador activo: Uptravi® (selexipag) film coated tablets
Uptravi® (selexipag) 400 microgram film coated tablets
|
1 tablet of Selexipag 400 microgram film coated tablets
1 tablet of Selexipag 400 microgram film coated tablets
1 tablet of Uptravi® (selexipag) 400 microgram film coated tablets
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Maximum concentration obtained (Cmax)
Periodo de tiempo: 20 hours
|
two-sides 90% CI for the test to reference ratio of the population means is within 80.00-125.00%
for each of the Ln-transformed data Cmax
|
20 hours
|
|
AUC from time 0 to last collection time (AUC0 - t)
Periodo de tiempo: 20 hours
|
two-sides 90% CI for the test to reference ratio of the population means is within 80.00-125.00%
for each of the Ln-transformed data AUC
|
20 hours
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Time to reach maximum concentration Cmax (Tmax)
Periodo de tiempo: 20 hours
|
Descriptive Statistics
|
20 hours
|
|
Area Under the Curve from time zero to time infinite (AUC0-infinite)
Periodo de tiempo: 20 hours
|
Descriptive Statistics
|
20 hours
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Patrocinador
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio (Actual)
8 de abril de 2026
Finalización primaria (Actual)
16 de junio de 2026
Finalización del estudio (Actual)
22 de junio de 2026
Fechas de registro del estudio
Enviado por primera vez
3 de julio de 2026
Primero enviado que cumplió con los criterios de control de calidad
3 de julio de 2026
Publicado por primera vez (Actual)
9 de julio de 2026
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
9 de julio de 2026
Última actualización enviada que cumplió con los criterios de control de calidad
3 de julio de 2026
Última verificación
1 de julio de 2026
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 25-VIN-0711
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
No
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
No
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .